Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Sells Anatrace Unit to Investment Firm StoneCalibre

Premium

StoneCalibre, a Los Angeles-based private investment firm, announced this week that it has acquired Affymetrix's Anatrace business unit. Financial details of the deal were not disclosed.

Anatrace develops, manufactures, and distributes detergents and synthetic lipids for use in membrane protein studies. Affymetrix gained the Maumee, Ohio-based business through its 2008 acquisition of reagents company USB (BAN 2/12/2008). The business has been maintained as part of Affymetrix's larger life science reagents unit, which generated $8 million in second quarter revenues and has been growing in the low single digits (BAN 8/6/2013).

According to StoneBridge, Anatrace will now become a standalone company. The firm tapped Ben Travis, who had been Affymetrix's life science reagents R&D director since 2005, to serve as CEO and president of the new company.

StoneCalibre CEO Brian Wall said in a statement that the investment company believes that under his firm's ownership Anatrace will "continue to build on its tradition of collaborating with its global customer base to help answer critical questions in the advancement of important studies across multiple scientific fields including cancer research."

StoneCalibre was founded last year. The company in June acquired Source Technologies, a Charlotte, NC-based provider of magnetic ink character recognition laser printers, consumables, maintenance, software, and accessories targeted primarily to the banking industry.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.